LakeShore Biopharma Warrants
LSBPW
LSBPW was delisted on the 19th of September, 2025.
21 hedge funds and large institutions have $346K invested in LakeShore Biopharma Warrants in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3.25% less ownership
Funds ownership: 5.3% → 2.05% (-3.3%)
9% less funds holding
Funds holding: 23 → 21 (-2)
31% less capital invested
Capital invested by funds: $501K → $346K (-$155K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Ovata Capital Management
Hong Kong
|
+$9.46K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$1.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$66.4K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$6.71K |
| 3 |
EAM
Exos Asset Management
New York
|
-$4.4K |
| 4 |
CAC
Cowen and Company
New York
|
-$1.21K |
| 5 |
CS
Clear Street
New York
|
-$84 |
LSBPW Hedge Fund Activity: Q3 2024 in Review
21 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q3 2024, worth a combined $346K — down 31% from $501K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSBPW and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Ovata Capital Management, opening a new position worth an estimated $9.46K. The largest seller was LMR Partners, exiting entirely with an estimated $66.4K sold.
- 21 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q3 2024, down from 23 in Q2 2024.
- Funds reported $346K of LakeShore Biopharma Warrants stock for Q3 2024, down 31% quarter-over-quarter.
- 2 funds opened new LakeShore Biopharma Warrants positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest LakeShore Biopharma Warrants buyer in Q3 2024 was Ovata Capital Management, an estimated $9.46K added.
- The largest LakeShore Biopharma Warrants seller in Q3 2024 was LMR Partners, an estimated $66.4K sold.
Based on aggregated 13F filings for Q3 2024.